HAE — Haemonetics Corporation stock price, charts and financials

QT71Haemonetics Corporation

Haemonetics Corporation (NYSE: HAE) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
107.60
+1.36+1.28%
HAEQT71Haemonetics Corporation·NYSE
107.60+1.28%
Analyst
Up 1.3% — Citigroup upgraded to Buy.
High confidence
TA
Loading chart...
Signal & projected range
Analyst upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E52.75EPS (ttm)2.04Insider Own2.41%Shs Outstand45.45MPerf Week6.47%
Market Cap4.89BForward P/E18.75EPS next Y5.74Insider Trans0.00%Shs Float44.84MPerf Month2.82%
Enterprise Value5.84BPEG5.42EPS next Q1.30Inst Own-Short Float6.39%Perf Quarter47.94%
Income97.00MP/S3.62EPS this Y159.65%Inst Trans-Short Ratio3.40Perf Half Y80.78%
Sales1.35BP/B5.84EPS next Y8.35%ROA4.07%Short Interest2.86MPerf YTD34.25%
Book/sh18.42P/C21.93EPS next 5Y9.74%ROE11.35%52W High109.83 -2.03%Perf Year110.90%
Cash/sh4.91P/FCF16.03EPS past 3/5Y-2.91% 5.75%ROIC8.61%52W Low47.32 127.39%Perf 3Y19.61%
Dividend Est.-EV/EBITDA22.38Sales past 3/5Y4.50% 8.92%Gross Margin57.38%Volatility2.86% 2.44%Perf 5Y63.87%
Dividend TTM-EV/Sales4.32EPS Y/Y TTM-38.37%Oper. Margin18.18%ATR (14)3.00Perf 10Y185.03%
Dividend Ex-Date-Quick Ratio1.92Sales Y/Y TTM-0.73%Profit Margin7.12%RSI (14)70.50Recom2.48
Dividend Gr. 3/5Y-Current Ratio3.08EPS Q/Q-8.06%SMA202.52%Beta0.61Target Price108.60
Payout0.00%Debt/Eq1.54Sales Q/Q5.61%SMA5016.41%Rel Volume0.85Prev Close106.24
Employees3,009LT Debt/Eq1.53EarningsNov 05SMA20045.91%Avg Volume732.08KPrice107.60
IPO DateMay 10, 1991Option/ShortYes / YesEPS/Sales Surpr.5.87% 3.51%Net Debt/EBITDA3.64Volume621,110Change1.28%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-17-26UpgradeCitigroupNeutralBuy
Sep-03-26ReiteratedRaymond JamesOutperform$105$125
Aug-21-26ReiteratedRobert W. Baird$96$119
Aug-19-26ReiteratedBarrington ResearchOutperform$95$118
Aug-07-26ReiteratedRaymond JamesOutperform$90$105
Aug-07-26ReiteratedRobert W. Baird$88$96
Aug-07-26ReiteratedBarringtonOutperform$89$95
Aug-06-26ReiteratedBTIGBuy$88$96
Jun-15-26ReiteratedMizuhoOutperform$70$85
May-22-26UpgradeB of A SecuritiesNeutralBuy
Latest News· Times ET
Sep-15-26
Sep-09-26
Sep-08-26
Sep-03-26
Aug-31-26
Aug-28-26
Aug-27-26
Aug-25-26
Aug-24-26
Aug-21-26
Aug-19-26
Aug-18-26
Company

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
3/28/2026
FY 2025
3/29/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue1,3511,3341,361
Cost of Goods Sold Incl. D&A577590582
Gross Profit775744779
Selling, General and Administrative Excl. Other451442422
Research and Development596069
Other Operating Expense20066
Operating Income245241222
Interest Expense302910
Unusual Expense
Non-Operating Income (Expense)-84-850
Net Income Before Taxes131128212
Income Taxes353144
Consolidated Net Income9797168
Net Income From Continuing Operations9797168
Net Income9797168
EPS (Recurring)2.062.053.31
EPS (Basic, Before Extraordinaries)2.062.053.31
EPS (Diluted)2.042.053.31
EBITDA261312356
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio52.7526.3619.09
Price To Sales Ratio3.581.902.32
Gross Margin57.3655.7757.24
Operating Margin18.1318.0716.31
Net Margin7.187.2712.34
Shares Outstanding454750
Market Capitalization4,8422,5403,160
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$117.97$98.10$78.23$58.37$38.50 Close Price0.00K24.70K49.39K74.09K98.78KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
KROLL MARK WDirectorNov 10 '25Buy70.561,40098,78424,757Nov 12
Strong Stewart WPresident, Global HospitalJul 26 '24Sale91.154,312393,03918,196Jul 29
Lingamneni AnilaEVP, Chief Technology OfficerJul 12 '24Sale90.00797,11021,331Jul 15
Lingamneni AnilaEVP, Chief Technology OfficerJul 11 '24Sale90.002,136192,24021,410Jul 15
Simon, ChristopherPresident & CEOJun 06 '24Option Exercise41.64104,5164,352,046433,877Jun 07
Basil Michelle LEVP and General CounselMay 29 '24Sale88.0812,9901,144,20931,257May 29
Strong Stewart WPresident, Global HospitalMay 29 '24Sale87.538,857775,25318,196May 29
Strong Stewart WPresident, Global HospitalMay 20 '24Option Exercise56.572,241126,77320,437May 21
Strong Stewart WPresident, Global HospitalMay 20 '24Sale95.1168665,24518,196May 21
Basil Michelle LEVP and General CounselMay 20 '24Sale95.081,604152,50831,257May 21
Llorens JosepEVP, Global ManufacturingMay 20 '24Sale95.0898793,84421,310May 21
Basil Michelle LEVP and General CounselMay 17 '24Sale95.001,073101,93529,352May 21
Llorens JosepEVP, Global ManufacturingMay 17 '24Sale94.8282277,94216,350May 21
Strong Stewart WPresident, Global HospitalMay 16 '24Sale96.0473370,39715,608May 17
Basil Michelle LEVP and General CounselMay 16 '24Sale96.1498594,69830,425May 17
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.